PI3Kα-IN-32
PI3Kα-IN-32 (Compound 11f) is a selective, orally active PI3Kα inhibitor, with an IC50 of 26.3 nM against PI3KαH1047R. PI3Kα-IN-32 inhibits AKT phosphorylation. PI3Kα-IN-32 exhibits anticancer activity against breast cancer. PI3Kα-IN-32 can be used in the research of HR+/HER2- breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 3057582-20-1
- Formula: C20H18F5N5O2S
- Molecular Weight:487.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PI3Kα-H1047R 26.3 nM (IC50) |
PI3Kα 94.6 nM (IC50) |
In Vitro
PI3Kα-IN-32 potently and selectively inhibits the enzymatic activity of the PI3KαH1047R mutant, with an IC50 of 26.3 nM[1].
PI3Kα-IN-32 (maximum 10 μM; 144 h) potently inhibits the proliferation of T47D HR+/HER2- breast cancer cells with an IC50 of 88.8 nM, and is 14.7-fold more selective for SK-BR-3 breast cancer cells expressing wild-type PI3Kα than for the former[1].
PI3Kα-IN-32 inhibits AKT phosphorylation in T47D HR+/HER2- breast cancer cells with an IC50 of 29.0 nM, and shows 5.8-fold selectivity for SK-BR-3 breast cancer cells expressing wild-type PI3Kα over the former[1].
PI3Kα-IN-32 (10 μM) exhibits high selectivity for PI3Kα, shows only weak activity against PI3Kδ and PIK3C3, and has no significant activity against the other 108 tested kinases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:T47D HR+/HER2- breast cancer cells, SK-BR-3 wild-type PI3Kα breast cancer cells
-
Concentration:10 μM (max, serial 4-fold dilutions)
-
Incubation Time:144 h
-
Result:Inhibited T47D cell proliferation with an IC50 of 88.8 nM.
Inhibited SK-BR-3 cell proliferation with an IC50 of 1307.5 nM, giving a T47D/SK-BR-3 selectivity ratio of 14.7.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c Nude (female, 6-8 weeks old, subcutaneous inoculation of T47D cells with 17β-estradiol tablet implantation)[1]
-
Dosage:50 mg/kg; 100 mg/kg; 150 mg/kg
-
Administration:p.o.; QD; 21 days
-
Result:Produced 77% tumor growth inhibition (TGI = 0.77) at 50 mg/kg.
Attained complete tumor regression at 100 mg/kg (TGI = 1.06) and 150 mg/kg (TGI = 1.19).
Showed no significant body weight loss at all tested dosages.
Caused no significant changes in plasma insulin levels at 4 h and 24 h post-dose.
Decreased tumor p-AKT (Ser473) levels by over 90% within 4 h of oral administration.
Confirmed dose-dependent inhibition of AKT phosphorylation in tumor tissue after treatment.
Chemical Information
-
CAS No. 3057582-20-1
-
Molecular Weight 487.45
-
Formula C20H18F5N5O2S
-
SMILES
OC(C1)(C)CN1C(N=C2)=NC=C2NC(N[C@H](C3=C(C)C4=C(C(F)=CC(F)=C4)S3)C(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)